Background. A high prevalence of chloroquine-resistant Plasmodium vivax in Indonesia has
shifted first-line treatment to artemisinin-based combination therapies, combined with …

Background Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but
the optimum duration of treatment and best partner drug are uncertain. A randomized …

Background Chloroquine has been recommended for Plasmodium vivax infections for> 60
years, but resistance is increasing. To guide future therapies, the cumulative benefits of …

Background. Chloroquine (CQ) remains the treatment of choice for Plasmodium vivax
malaria. Initially confined to parts of Indonesia and Papua, resistance of P. vivax to CQ …

Abstract Background. Chloroquine (CQ)-resistant Plasmodium vivax is increasingly reported
throughout southeast Asia. The efficacy of CQ and alternative artemisinin combination …

Background Plasmodium vivax malaria, with the widest geographic distribution, can cause
severe disease and death. Primaquine is the main licensed antimalarial drug that can kill …

Radical cure of Plasmodium vivax infection applies blood schizontocidal therapy against the
acute attack and hypnozoitocidal therapy against later relapse. Chloroquine and primaquine …

Afghanistan's national guidelines recommend primaquine (PQ) for radical treatment of
Plasmodium vivax malaria, but this is rarely implemented because of concerns over …

Background There is general international agreement that the importance of vivax malaria
has been neglected, and there is a need for new treatment approaches in an effort to …

Background Afghanistan's national guidelines recommend chloroquine for the treatment of
Plasmodium vivax infection, the parasite responsible for the majority of its malaria burden …